ClinicalTrials.gg
CompletedNCT03509012CLOVERUpdated Jan 14, 2025

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

A Phase 1 interventional study of Durvalumab and Tremelimumab in Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma, sponsored by AstraZeneca. Completed at 16 sites in 5 countries. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
5th of 20
105 · median 40
Started
2018
with 6 others
Phase 1
7 of 20
none open now
Registered
13th of 20
by date
Lead sponsor
4 of 20
AstraZeneca

Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one is the 5th largest by enrollment, is one of 7 that started in 2018, is one of 7 in phase 1, and was the 13th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck as a file.
02

Study summary

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Read the detailed description

This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).

03

Conditions studied

  • Carcinoma, Squamous Cell of Head and Neck
  • Carcinoma, Non-Small-Cell Lung
  • Small Cell Lung Carcinoma

Keywords

  • Durvalumab
  • Chemotherapy
  • Radiotherapy
  • HNSCC
  • NSCLC
  • SCLC
  • locally-advanced
  • limited stage
  • first line
04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • World Health Organization (WHO)/ performance status of 0 or 1
  • Body weight >30 kg at enrollment and treatment assignment
  • At least 1 , not previously irradiated
  • No prior exposure to immune-mediated therapy (including therapeutic anticancer vaccines)
  • For patients with oropharyngeal HNSCC HPV status has to be known

Exclusion criteria

Exclusion criteria:

  • Patients with simultaneous primary or bilateral tumors
  • Active or prior documented or inflammatory disorders
  • or spinal cord compression
  • Active infection including tuberculosis, , , or (HIV; positive HIV 1/2 antibodies)
  • Has a paraneoplastic syndrome (PNS) of autoimmune nature
  • HNSCC cohort: Head and neck cancer that does not include unresectable, locally advanced cancer of oral cavity, larynx, oropharynx or hypopharynx. HNSCC of unknown primary are also excluded
  • NSCLC and SCLC cohort: Mixed SCLC and NSCLC histology
  • SCLC cohort: Extensive-stage SCLC
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    HNSCC Arm 1

    Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)

    Drug: Durvalumab · Drug: Cisplatin (dose level 4) · Radiation: External beam radiation (dose level 1)

  • Experimental
    NSCLC Arm 1

    Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)

    Drug: Durvalumab · Drug: Etoposide (dose level 1) · Radiation: External beam radiation (dose level 2) · Drug: Cisplatin (dose level 1)

  • Experimental
    NSCLC Arm 2

    Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)

    Drug: Durvalumab · Drug: Carboplatin (dose level 1) · Drug: Paclitaxel · Radiation: External beam radiation (dose level 2)

  • Experimental
    NSCLC Arm 3

    Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed

    Drug: Durvalumab · Drug: Carboplatin (dose level 2) · Drug: Pemetrexed · Radiation: External beam radiation (dose level 2) · Drug: Cisplatin (dose level 2)

  • Experimental
    SCLC Arm 1

    Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin

    Drug: Durvalumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (standard)

  • Experimental
    SCLC Arm 2

    Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin

    Drug: Durvalumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (hyperfractionated)

  • Experimental
    SCLC Arm 3

    Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (standard)

  • Experimental
    SCLC Arm 4

    Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.

    Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin (dose level 3) · Drug: Carboplatin (dose level 2) · Drug: Etoposide (dose level 2) · Radiation: External beam radiation (hyperfractionated)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with Dose Limiting Toxicities (DLTs)

    Time frame: From first dose of durvalumab until 28 days after completion of radiation therapy

  2. Number of subjects with Adverse Events (AEs)

    Time frame: From first dose of durvalumab up to 90 days after the last dose of study treatment

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: From first dose until the date of objective disease progression or death, in the absence of progression at 12, 18 and 24 months, up to 4 years.

  2. Overall Survival (OS)

    Time frame: From first dose until death due to any cause through study completion, up to 4 years

  3. Objective response rate (ORR)

    Number (%) of patients with an overall response of complete response (CR) or partial response (PR).

    Time frame: From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.

  4. Best objective response (BoR)

    The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression.

    Time frame: From first dose until disease progression, or the last evaluable assessment in the absence of progression, assessed up to 4 years.

  5. Duration of response (DoR)

    Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression.

    Time frame: From first dose until disease progression, or death, in the absence of progression, assessed up to 4 years.

  6. Disease control rate (DCR)

    Time frame: From first dose until disease progression, at 18 weeks and 48 weeks.

  7. Disease-free survival (DFS)

    Time frame: From first dose until disease progression or death, in the absence of progression at 12, 18 and 24 months, assessed up to 4 years.

07

Study locations

16 sites
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taoyuan City, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2020, 31 months.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's 31 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Apr 26, 2018
StartActual
May 2, 2018
Primary completionActual
Dec 31, 2020
CompletionActual
Jan 8, 2025
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03509012
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 26, 2018
Start date
May 2, 2018
Primary completion
Dec 31, 2020
Completion
Jan 8, 2025
Last update
Jan 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab · Cisplatin · Carboplatin · Etoposide · Paclitaxel · Pemetrexed

Start the discussion